Atlas Trials

Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

Clinical trial NCT05266469 · COMPLETED

Trial details

NCT number
NCT05266469
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Study type
OBSERVATIONAL
Relapsing Multiple Sclerosis
Start date
2022-07-26
Primary completion
2024-11-11
Enrollment
168

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.